European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
2020 · Leukemia · 1,470 citations
https://doi.org/10.1038/s41375-020-0776-2
A
Anna Turkina
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
366
Papers
5.0K
Citations
25
h-index
59
i10-index
Anna Turkina is an academic researcher from National Medical Research Center for Hematology. The author has contributed to research in topics: Chronic Myeloid Leukemia Treatments & Chronic Lymphocytic Leukemia Research & Eosinophilic Disorders and Syndromes. The author has an h-index of 25, co-authored 312 publications.
ORCID: 0000-0001-9947-2371Papers by this author
worksAsciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL
2023 · Leukemia · 126 citations
https://doi.org/10.1038/s41375-023-01829-9
Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib
2008 · Biochemistry (Moscow) · 38 citations
https://doi.org/10.1134/s0006297908010045
Prognostic Value of P-Glycoprotein and Leukocyte Differentiation Antigens in Chronic Myeloid Leukemia
1998 · Leukemia & lymphoma/Leukemia and lymphoma · 24 citations
https://doi.org/10.3109/10428199809058354
Withdrawal Syndrome After Tyrosine Kinase Inhibitor Discontinuation in Patients With Chronic Myeloid Leukemia in the Russian Prospective Study RU-SKI
2020 · Clinical Lymphoma Myeloma & Leukemia · 14 citations
https://doi.org/10.1016/j.clml.2019.12.019
Asciminib remained superior vs bosutinib in late-line CML-CP after nearly 4 years of follow-up in ASCEMBL
2025 · Blood Advances · 6 citations
https://doi.org/10.1182/bloodadvances.2025016042
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat